*
*Life Sciences Leaders Convene in Boston**
On April 17, 2025, the Boston Life Sciences, Biotech, Pharma, and Medical Facilities Conference will bring together industry experts to tackle the sector's most pressing challenges. Purnanand Sarma, CEO of Aro Biotherapeutics and a seasoned leader with over three decades of experience in pharmaceuticals, will share his insights as the keynote speaker.
Sarma's impressive track record spans drug development, IPOs, M&A, and strategic asset transactions. As an operating CEO and board member for both private and public companies, he has consistently driven value creation. Currently at Aro Biotherapeutics, Sarma is pioneering siRNA-based therapeutics, including the lead product candidate ABX1100 for Pompe disease.
The conference, organized by Boston Real Estate Times and supported by Life Sciences Times, will provide a platform for industry professionals to discuss market trends, opportunities, and challenges in life sciences, biotech, and healthcare facilities. Key topics include:
* Market analysis: Emerging challenges and areas of weakness
* AI and policy impact: Examining the influence of emerging technologies and shifting policies on the sector
* Recovery timeline: Insights into the anticipated recovery of the Life Sciences sector
* Vacancy and rent trends: Strategies for adapting to new market conditions amidst a 26.9% vacancy rate in Life Sciences facilities
With over 15 million square feet of available space in the Greater Boston area, attendees will explore strategies for utilizing this surplus and its implications on the sector's future. Additionally, investor sentiment and short-term/long-term outlooks for venture capital funding in Life Sciences and biotech will be discussed.
**Join the Conversation**
Don't miss this opportunity to connect with leading voices shaping the future of Life Sciences, Biotech, Pharma, and Healthcare in the Greater Boston area. Register now (early bird rates available until March 20, 2025) or inquire about speaking engagements by contacting [email protected].
